Bristol Myers Squibb, has reached an agreement with the U.S. government to provide Eliquis, a widely used oral anticoagulant, to the Medicaid program at no cost and to donate over seven tons of Eliquis active pharmaceutical ingredient to strengthen the U.S. supply chain. This initiative reflects BMS’s ongoing commitment to cardiovascular health, improving patient outcomes, and collaborating with policymakers to lower healthcare costs while maintaining support for future innovation.
Health Technology Insights: Nemluvio Shows Rapid Itch Relief and Sleep Benefits
Christopher Boerner, Ph.D., Chair of the Board and Chief Executive Officer of Bristol Myers Squibb, stated that the agreement directly supports millions of Americans by ensuring access to this essential medication at no cost. He emphasized that this effort builds on BMS’s broader strategy to enhance affordability, promote transparency, and continue investing in the United States, where the company has a history of over 165 years in discovering and developing transformative medicines.
Eliquis is the most prescribed oral blood thinner in the United States, with over 15 million Americans having used the medication since its launch. It is a critical therapy for patients with atrial fibrillation not caused by heart valve problems, helping to prevent strokes and blood clots, and it is also used to treat and reduce recurrence of blood clots in the legs and lungs. For every 100,000 patients treated, Eliquis has been associated with approximately $3 billion in healthcare cost savings by avoiding hospitalization and extensive rehabilitation.
Health Technology Insights: Form Health Offers Clear, Predictable GLP-1 Coverage for Employers
The agreement addresses several key priorities. Eliquis will be provided to Medicaid at no cost starting January 1, 2026, reducing expenses for both patients and the healthcare system. BMS will donate more than seven tons of Eliquis active pharmaceutical ingredient to the U.S. Strategic Active Ingredient Reserve at no cost. The company will also introduce new medicines with balanced pricing across developed countries and expand direct-to-patient access for other therapies, offering discounts of approximately 80 percent off current list prices. Confidential terms also include three years of tariff relief and exemption from future pricing mandates.
As part of BMS’s commitment to invest $40 billion in the U.S. over five years, the company plans to expand domestic production of its medicines. Eliquis is promoted through the Bristol Myers Squibb-Pfizer Alliance. The medication is indicated for adults to reduce the risk of stroke and blood clots in atrial fibrillation not caused by a heart valve problem, prevent and treat deep vein thrombosis and pulmonary embolism, and for children from birth to treat venous thromboembolism after initial anticoagulant therapy. Patients should be aware of the risks, including increased clotting if the medicine is stopped abruptly and potential bleeding complications, and must follow medical guidance closely.
Health Technology Insights: FDA Approves Exdensur (Depemokimab) for Severe Asthma
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- businesswire
